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Renal cell carcinoma (RCC) is one of the most common cancers. The prevalence of RCC and the mortality rate have both increased over the past decade.[1](#cas12951-bib-0001){ref-type="ref"} Within the European Union, more than 80 000 new cases were diagnosed in 2012, and there were approximately 35 000 related deaths.[2](#cas12951-bib-0002){ref-type="ref"} Despite advances in cross‐sectional imaging techniques and increased opportunity for the incidental detection of RCC during examination for unrelated diseases, approximately 30% of RCC patients already harbor metastatic disease.[1](#cas12951-bib-0001){ref-type="ref"} Furthermore, another 20% of patients who were undertaken nephrectomy resulted in development of mRCC during follow‐up.[3](#cas12951-bib-0003){ref-type="ref"} Therefore, establishing an optimized treatment strategy for metastatic disease is a major issue that needs to be addressed in order to improve survival of RCC patients.

IFN‐α was among the most commonly used agents for mRCC before molecular targeted agents became available. Although its objective response rate is around 10%[4](#cas12951-bib-0004){ref-type="ref"}, [5](#cas12951-bib-0005){ref-type="ref"}, [6](#cas12951-bib-0006){ref-type="ref"}, [7](#cas12951-bib-0007){ref-type="ref"} and the latest guidelines recommend its usage for clear cell carcinoma only by simultaneous administration with bevacizumab,[8](#cas12951-bib-0008){ref-type="ref"} for several reasons it is still used as a single agent for Japanese mRCC patients. First, it provides a fairly favorable prognosis in these patients in the cytokine era.[9](#cas12951-bib-0009){ref-type="ref"} Second, patients are more likely to achieve complete response than if treated with molecular targeted agents.[10](#cas12951-bib-0010){ref-type="ref"} Third, molecular targeted agents induce more frequent adverse events in Japanese mRCC patients than in Caucasian patients.[11](#cas12951-bib-0011){ref-type="ref"}

In our previous case‐control association study conducted in 2007, a particular SNP in *STAT3*, frequently observed in Japanese people compared to Caucasian people, predicts a better response to IFN‐α,[12](#cas12951-bib-0012){ref-type="ref"} supporting the idea that IFN‐α is a useful therapeutic option in Japanese mRCC patients. Hence, it is reasonable to expect that a substantial fraction of Japanese mRCC patients can still be given IFN‐α as a first‐line therapy even in the post‐cytokine era. In fact, our recent multi‐centre prospective study (the RCC‐SELECT study) demonstrated that STAT3‐2 (rs1905341) is significantly associated with better clinical response (complete response, partial response and stable disease longer than 24 weeks) and better overall survival (OS) in Japanese mRCC patients with first‐line IFN‐α therapy in the post‐cytokine era.[10](#cas12951-bib-0010){ref-type="ref"} Notably, in that study, even the one genotypic cohort (with C/T or T/T in STAT3‐2) with shorter survival exhibited prolonged median OS (41.8 months) compared to the previous studies (median OS of the C/C genotype cohort had not been reached at the time of the previous analysis).[7](#cas12951-bib-0007){ref-type="ref"}, [9](#cas12951-bib-0009){ref-type="ref"} This suggests that the recent prognosis of mRCC patients who received first‐line IFN‐α therapy has been significantly improved compared to the cytokine era regardless of genetic background. However, factors affecting the prognosis of such patients have not yet been fully studied. The aim of the present study is to estimate OS and to identify prognostic factors of mRCC patients whose first‐line therapy was IFN‐α in the era of molecular targeted therapy by analyzing the cohort of the RCC‐SELECT study.

Materials and Methods {#cas12951-sec-0002}
=====================

Patients and study design {#cas12951-sec-0003}
-------------------------

The RCC‐SELECT study was a multicenter, prospective study evaluating the correlation between the antitumor effects of IFN‐α and 11 SNP in eight genes in 180 patients who were treated with three doses per week of IFN‐α 5 million IU for 12 weeks or longer. Details of this study design, including eligibility criteria and endpoints, have been published previously,[10](#cas12951-bib-0010){ref-type="ref"} and the present study includes all patients who were eligible in the previous study. Histology of patients includes 168 clear cell RCC (93.3%), 9 papillary RCC (5.0%) and 3 RCC with unknown histology (1.7%). The protocol of the present study was approved by the ethics committees of all the clinical sites, and all patients provided written informed consent.

Statistical analysis {#cas12951-sec-0004}
--------------------

Overall survival was calculated from the date when the first IFN‐α administration was given to the date of death as a result of any cause or the date of the last follow‐up. OS was analyzed using the Kaplan--Meier method, and median OS and hazard ratio along with 95% confidence limits are described. Associations between OS and potential prognostic factors were assessed using the log‐rank test in univariate analysis. Two‐sided *P \<* 0.05 was considered significant. A stepwise Cox proportional hazards model was performed to determine a combination of factors that were jointly significantly associated with OS. Statistical analyses were performed with SAS v.8.2 (SAS Institute, Cary, NC, USA).

Results {#cas12951-sec-0005}
=======

A total of 211 patients with mRCC were enrolled in the previous study, and 203 patients were judged to be eligible, whose characteristics are shown in Table [1](#cas12951-tbl-0001){ref-type="table-wrap"}.[10](#cas12951-bib-0010){ref-type="ref"} Among those patients, 180 patients who could continue the IFN‐α therapy for longer than 12 weeks were evaluated in the RCC‐SELECT study. Data regarding these 180 patients were further analyzed in the present study. The median OS of the patients was 42.8 months (Fig. [1](#cas12951-fig-0001){ref-type="fig"}). Then, relationships between patient demographics/clinicopathological parameters and OS were investigated (Table [2](#cas12951-tbl-0002){ref-type="table-wrap"}). Regarding patient characteristics, better ECOG‐performance status (ECOG‐PS) (0 *vs* 1) was significantly associated with longer OS (hazard ratio \[HR\] = 2.728, *P* = 0.0006). Regarding TNM classification, high T stage (T2, T3 and T4 *vs* T1) (*R* = 2.132, *P* = 0.0298), the presence of regional lymph node metastasis (N1 and N2 *vs* N0) (HR = 2.092, *P* = 0.0033) and distant metastasis (M1 *vs* M0) (HR = 1.961, *P* = 0.0365) were significantly associated with shorter OS. Regarding pathological features, while expansive growth pattern was related to longer OS than infiltrative growth pattern (HR = 0.571, *P* = 0.0382), higher grade (G3 *vs* G1 and G2) (HR = 2.587, *P* = 0.0002) and the presence of MVI (HR = 3.322, *P* = 0.0004) were significantly associated with shorter OS. In contrast, neither the presence of sarcomatoid component (HR = 1.657, *P* = 0.2721) nor sites of metastasis (lung only metastasis *vs* metastasis involving other sites) (HR = 0.688, *P* = 0.1131) were related to OS. Regarding laboratory measurements, hypercalcemia (HR = 2.616, *P* = 0.0010), anemia (HR = 2.214, *P* = 0.0008), thrombocytosis (HR = 2.704, *P* = 0.0009) and elevated C‐reactive protein (CRP) (HR = 2.158, *P* = 0.0013) were significantly associated with shorter OS. Elevated lactate dehydrogenase was not associated with OS (HR = 3.305, *P* = 0.0782) probably because only two patients (1%) exhibited this abnormality. Finally, the significant variables associated with OS on univariate analysis were entered into a stepwise Cox regression model, resulting in the following three factors: ECOG‐PS (HR = 3.665, *P* = 0.0004), the presence of MVI (HR = 6.428, *P* = 0.0005) and hypercalcemia (HR = 2.668, *P* = 0.0109) (Table [3](#cas12951-tbl-0003){ref-type="table-wrap"}). Survival curves for patients with or without those factors are shown in Figure [2](#cas12951-fig-0002){ref-type="fig"}(a--c).

###### 

Summary of patient characteristics

  ------------------------------------- -------------
  Patients, number                      180
  Age, year, median (range)             68 (40--85)
  Sex, number (%)                       
  Male                                  147 (81.7)
  Female                                33 (18.3)
  ECOG performance status, number (%)   
  0                                     161 (89.4)
  1                                     19 (10.6)
  TNM classification, number (%)        
  T                                     
  T1                                    39 (21.7)
  T2 or above                           138 (76.7)
  Tx                                    3 (1.7)
  N                                     
  N0                                    137 (76.1)
  N1 or above                           38 (21.1)
  Nx                                    5 (2.8)
  M                                     
  M0                                    39 (21.7)
  M1                                    138 (76.7)
  Mx                                    3 (1.7)
  Histologic grade, number (%)          
  G1                                    15 (8.3)
  G2                                    109 (60.6)
  G3                                    48 (26.7)
  GX                                    8 (4.4)
  Site of metastases, number (%)        
  Lung only                             120 (66.7)
  Lung and other sites                  24 (13.3)
  Other sites                           36 (20.0)
  ------------------------------------- -------------
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![Overall survival of 180 patients with metastatic renal cell carcinoma treated with IFN‐α. Median overall survival (OS) is 42.8 month (95% confidence interval: 37.1‐NA). NA, not available.](CAS-107-1013-g001){#cas12951-fig-0001}

###### 

Univariate analysis of association between patient demographics/clinicopathological parameters and overall survival

  Factors                         *N*   Median overall survival (days)   Hazard ratio (95% confidence interval)   *P*‐value
  ------------------------------- ----- -------------------------------- ---------------------------------------- -----------
  Age                                                                                                             
  ≥65                             108   1306                             0.981 (0.617--1.562)                     0.9363
  \<65                            72    1352                                                                      
  ECOG‐PS                                                                                                         
  0                               161   1352                             2.728 (1.496--4.976)                     0.0006
  1                               19    466                                                                       
  TNM classification                                                                                              
  T                                                                                                               
  T1                              39    Not reached                      2.132 (1.060--4.291)                     0.0298
  T2 or above                     138   1274                                                                      
  N                                                                                                               
  N0                              137   1453                             2.092 (1.264--3.464)                     0.0033
  N1 or above                     38    807                                                                       
  M                                                                                                               
  M0                              39    1453                             1.961 (1.031--3.729)                     0.0365
  M1                              138   1282                                                                      
  Growth pattern                                                                                                  
  Expansive                       107   1352                             0.571 (0.334--0.977)                     0.0382
  Infiltrative                    34    736                                                                       
  Grade                                                                                                           
  1 or 2                          124   1453                             2.587 (1.573--4.254)                     0.0002
  3                               48    728                                                                       
  Sarcomatous component                                                                                           
  No                              169   1352                             1.657 (0.666--4.124)                     0.2721
  Yes                             11    848                                                                       
  Microscopic vascular Invasion                                                                                   
  No                              50    Not reached                      3.322 (1.644--6.713)                     0.0004
  Yes                             112   1070                                                                      
  Site of metastasis                                                                                              
  Lung only                       120   Not reached                      0.688 (0.432--1.096)                     0.1131
  Others                          60    1274                                                                      
  Lactate dehydrogenase                                                                                           
  \<1.5×ULN                       168   1352                             3.305 (0.807--13.542)                    0.0782
  ≥1.5×ULN                        2     619                                                                       
  Corrected Ca (mg/dL)                                                                                            
  \<10                            136   1352                             2.616 (1.442--4.744)                     0.0010
  ≥10                             21    583                                                                       
  Hemoglobin (mg/dL)                                                                                              
  ≤LLN                            89    1070                             2.214 (1.372--3.573)                     0.0008
  \>LLN                           87    Not reached                                                               
  C‐reactive protein (mg/dL)                                                                                      
  \<0.3                           81    1361                             2.158 (1.334--3.491)                     0.0013
  ≥0.3                            94    848                                                                       
  Platelet count (/μL)                                                                                            
  \<400 000                       154   1361                             2.704 (1.468--4.980)                     0.0009
  ≥400 000                        22    524                                                                       
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###### 

Multivariate analysis of association between patient factorsand overall survival

  Factors                                       *P*‐value   Hazard ratio   95% CI
  --------------------------------------------- ----------- -------------- ---------------
  ECOG‐PS (0 *vs* 1)                            0.0004      3.665          1.785--7.527
  Microscopic vascular invasion (No *vs* Yes)   0.0005      6.428          2.254--18.332
  Corrected Ca (mg/dL) (\<10 *vs* ≥10)          0.0109      2.668          1.253--5.682
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![Overall survival of patients treated with IFN‐α: (a) ECOG‐PS 0 versus 1, (b) with versus without microscopic vascular invasion (MVI) and (c) corrected Ca^++^ \<10 mg/dL versus 10 mg/dL or above.](CAS-107-1013-g002){#cas12951-fig-0002}

Discussion {#cas12951-sec-0006}
==========

This is an extended analysis of the RCC‐SELECT study[10](#cas12951-bib-0010){ref-type="ref"} that confirmed the correlation between the clinical response of IFN‐α therapy for mRCC and a *STAT3* SNP (rs1905341). We observed a marked improvement in patients\' OS (42.8 months) when compared to patients\' in studies in the cytokine era with either the same or different racial backgrounds.[7](#cas12951-bib-0007){ref-type="ref"}, [9](#cas12951-bib-0009){ref-type="ref"}, [13](#cas12951-bib-0013){ref-type="ref"} It is of note that the present study is based on the cohort of the first and hitherto largest prospective study on mRCC patients whose first‐line therapy was IFN‐α in the post‐cytokine era.[12](#cas12951-bib-0012){ref-type="ref"} This endorses the accuracy of the results for the following reasons: (i) the collection of precise data regarding the patient demographics and clinical parameters; and (ii) the careful follow‐up until events took place or the observation was finished. Although there are some differences in patient demographics (e.g. PS, metastasis sites and frequency of prior nephrectomy) between the previous and present studies in addition to study design, the greatest contributing factor is the emergence of molecular targeted agents. Because the patient enrollment of the original RCC‐SELECT study commenced in December 2006, only 18 months before the introduction of sorafenib and sunitinib for mRCC in Japan, it is highly likely that the vast majority of patients enrolled in this study benefited from those molecular targeted agents following first‐line IFN‐α therapy. Notably, Shinohara *et al*.[14](#cas12951-bib-0014){ref-type="ref"} report in their retrospective study that the median OS was 38.2 months in the mRCC patients with the same racial background whose first‐line therapy was cytokine in the era of molecular‐targeted therapy. This strongly supports the result of the present study that the prognosis of mRCC patients whose first‐line therapy was IFN‐α has been remarkably improved.

Intriguingly, in an extended analysis of the AXIS trial comparing axitinib versus sorafenib as a second‐line treatment for mRCC, patients previously treated with cytokines including IFN‐α exhibited significantly longer progression free survival and OS from the start of first‐line therapy than those previously treated with sunitinib in both axitinib and sorafenib treated groups.[15](#cas12951-bib-0015){ref-type="ref"} This suggests that first‐line IFN‐α therapy followed by VEGF‐TKI may provide longer survival than sequencing two different VEGF‐TKI in a substantial fraction of mRCC patients. Considering the result of the landmark trial comparing IFN‐α versus sunitinib by Motzer *et al*.[16](#cas12951-bib-0016){ref-type="ref"} such a result appears paradoxical. However, there are some possible explanations for this outcome: (i) tumors may have acquired resistance to VEGF‐TKI during first‐line sunitinib treatment, resulting in diminished efficacy with second‐line VEGF‐TKI;[17](#cas12951-bib-0017){ref-type="ref"} and (ii) administration of cytokines including IFN‐α provokes generation and persistence of memory T cells that can recognize tumor epitopes,[18](#cas12951-bib-0018){ref-type="ref"} and such memory T cells might be ignited by peptide released from dying tumor cells during VEGF‐TKI treatment,[19](#cas12951-bib-0019){ref-type="ref"} resulting in enhancement of anti‐cancer immunity.

In the present study, multivariate analysis revealed that PS, hypercalcemia and MVI are the independent prognostic factors. Hypercalcemia is the most frequent paraneoplastic complication of mRCC, being manifested in up to 20% of RCC patients during the course of their disease[20](#cas12951-bib-0020){ref-type="ref"}, [21](#cas12951-bib-0021){ref-type="ref"} and known to imply a poor prognosis because of its frequent association with disseminated disease. Previous reports suggested that humoral factors such as PTHrP,[22](#cas12951-bib-0022){ref-type="ref"} IL‐6[23](#cas12951-bib-0023){ref-type="ref"} and prostaglandins[24](#cas12951-bib-0024){ref-type="ref"} may play roles in hypercalcemia either directly or indirectly by increasing bone resorption. Since Motzer *et al*.[7](#cas12951-bib-0007){ref-type="ref"} identified hypercalcemia as an independent prognostic factor in mRCC patients treated with IFN‐α, it has been included in other prognosis prediction models for mRCC from the cytokine era to the target therapy era.[7](#cas12951-bib-0007){ref-type="ref"}, [25](#cas12951-bib-0025){ref-type="ref"}, [26](#cas12951-bib-0026){ref-type="ref"}, [27](#cas12951-bib-0027){ref-type="ref"}, [28](#cas12951-bib-0028){ref-type="ref"} Interestingly, the largest retrospective analysis so far regarding prognostic factors for survival in mRCC patients treated with sunitinib revealed that hypercalcemia is the only factor among the MSKCC\'s criteria[7](#cas12951-bib-0007){ref-type="ref"} for OS in multivariate analysis.[28](#cas12951-bib-0028){ref-type="ref"} Therefore, hypercalcemia may be a prognostic factor for metastatic renal cell carcinoma regardless of the type of systemic therapy.

The importance of MVI as a prognostic factor in RCC is also well documented in the published literature.[29](#cas12951-bib-0029){ref-type="ref"}, [30](#cas12951-bib-0030){ref-type="ref"}, [31](#cas12951-bib-0031){ref-type="ref"} It is histologically obvious that MVI requires a local destruction of the venous wall by the tumor cells. However,, it is also significantly associated with other prognostic factors such as tumor size, Fuhrman grade, pathological stage and the presence of sarcomatoid elements.[29](#cas12951-bib-0029){ref-type="ref"}, [30](#cas12951-bib-0030){ref-type="ref"}, [31](#cas12951-bib-0031){ref-type="ref"} This suggests that MVI is not merely a manifestation of tumor cell entry into the circulation, but also an indicator of malignant potential. However, the previous studies indicating MVI as a prognostic factor were based on the analysis of patients with clinically localized RCC who underwent radical or partial nephrectomy, but not those with metastasis at the time of diagnosis. Conversely, in previous studies investigating survival of mRCC patients subjected to systemic therapy, MVI was not shown as a prognostic factor. This is probably because not all patients that participated in such studies underwent prior nephrectomy; therefore, analyses regarding the relationship between survival and histological details of tumors may not have been feasible. In this sense, this is the first study showing that MVI is a prognostic factor also in mRCC patients who received systemic therapy because it includes prior nephrectomy as a study criterion that enables analysis for correlation between histological factors such as MVI and overall survival in mRCC patients.

A limitation of the present study is that it only included patients with limited racial background. Hence, external validation with other racial backgrounds is needed. The present study suggests that IFN‐α is still a valid agent for mRCC for first‐line treatment even in the era of molecular targeted therapy. For such a treatment strategy, PS, hypercalcemia and MVI are independent predictors of survival, which will be particularly useful information for selecting appropriate patients. Although IFN‐α appeared inferior to molecular targeted agents in the previous clinical trial settings,[16](#cas12951-bib-0016){ref-type="ref"}, [32](#cas12951-bib-0032){ref-type="ref"}, [33](#cas12951-bib-0033){ref-type="ref"} we have to reconsider its actual efficacy and contemporary role in mRCC treatment in the context of sequential therapy with molecular targeted agents. Further studies are warranted to identify optimal combination of IFN‐α and following molecular targeted agents for attaining better outcomes.
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